Close
Nordic 9Nordic 9

Brandon Capital Partners (investor - Venture Capital)

Australia brandoncapital.com.au
See something wrong or missing? Let us know
Offices:Melbourne
Average round investment:67.95M USD
Average number per year:2.0
Distribution: 2025 (1)2024 (4)2023 (1)2022 (3)2020 (1)
Portfolio companies: United Kingdom NRG TherapeuticsGermany CatalYmUnited Kingdom Myricx Bio See the entire list
Mostly invests in: United Kingdom United Kingdom (8) Health services (10)
See the entire list

Showing 3 of 10 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Brandon Capital Partners mostly invests with:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Brandon Capital Partners

Name Criteria
Germany Bosch Ventures
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom, Germany
  • Average number of deals per year: 2.1
  • Active last 12 months: Yes
Sweden Summa Equity
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 3.0
  • Active last 12 months: Yes
United Kingdom SV Health Investors
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Pharma, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 3.0
  • Active last 12 months: Yes
United Kingdom Oxford Technology and Innovations EIS Fund
82%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Pharma, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 3.4
  • Active last 12 months: Yes
United States RA Capital Management
82%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Pharma, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Germany
  • Average number of deals per year: 3.8
  • Active last 12 months: Yes
United States Koch Disruptive Technologies
82%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 4.0
  • Active last 12 months: Yes
United States Northpond Ventures
82%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Pharma, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom, Germany
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
United States Bristol-Myers Squibb
82%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Pharma, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom, Germany
  • Average number of deals per year: 1.8
  • Active last 12 months: Yes
France Sanofi Ventures
82%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Pharma, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 2.2
  • Active last 12 months: Yes
United Kingdom Syncona
82%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Pharma, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 2.3
  • Active last 12 months: Yes
Top